Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,779
datasets available to search
ShareScore release 0.9.0
Dataset results
1,779 results for “Hodgkin lymphoma”
Expression data from EBER1-overexpressing Hodgkin lymphoma cell lines KM-H2 and L428
GEO Series GSE12427. Homo sapiens. 4 samples. Type: Expression profiling by array.
Hepatitis virus-associated B cell non-Hodgkin’s lymphoma involves dysregulated epigenetic and RNA-mediated regulatory gene expression and altered snoRNA transcription
GEO Series GSE279755. Homo sapiens. 26 samples. Type: Expression profiling by high throughput sequencing.
Combinatorial Ixazomib and Belinostat Therapy Induce Nuclear Factor Erythroid 2-Related Factor 2 (NRF2)-Dependent Apoptosis in Hodgkin and T-cell Lymphoma
GEO Series GSE126768. Homo sapiens. 24 samples. Type: Expression profiling by array.
Gene expression profile of classical Hodgkin lymphoma according to Epstein-Barr infection status
GEO Series GSE21586. Homo sapiens. 8 samples. Type: Expression profiling by array.
5' gene expression (GEX) single-cell RNA sequencing of four (4) Hodgkin Lymphoma patient tumor biopsies
GEO Series GSE232761. Homo sapiens. 5 samples. Type: Expression profiling by high throughput sequencing.
CD19 Chimeric Antigen Receptor Engineered NK92 Natural Killer Cells: Novel “Off the Shelf” Immunotherapy in Non-Hodgkin Lymphoma I
GEO Series GSE120315. Homo sapiens. 36 samples. Type: Expression profiling by array.
Hodgkin lymphoma
GEO Series GSE25990. Homo sapiens. 16 samples. Type: Expression profiling by array; Genome variation profiling by SNP array.
miRNA expression in classical Hodgkin lymphoma diseased nodes
GEO Series GSE45264. Homo sapiens. 22 samples. Type: Non-coding RNA profiling by array.
EZH2 suppresses the interferon-stimulated gene response in non-Hodgkin Lymphoma [RNA-seq]
GEO Series GSE70622. Homo sapiens. 12 samples. Type: Expression profiling by high throughput sequencing.
Lipid addiction via Fatty Acid Synthase activates PI3K signaling in B cell non-Hodgkin’s Lymphoma (bNHL) [SUDHL2, SUHDL10, and Raji]
GEO Series GSE102791. Homo sapiens. 33 samples. Type: Expression profiling by array.
Hodgkin Lymphoma International Study for Individual Care
Our goal is to enhance decision support and promote personalized medicine for Hodgkin lymphoma patients across all disease states and stages, given expanding treatment options, and in the absence of complete acute and long-term data. To accomplish this, we sought to unify and harness worldwide, multi-source data to define acute, post-acute, and long-term outcomes for individual Hodgkin lymphoma patients. We have harmonized individual patient data (IPD) from more than 15 contemporary Hodgkin lymphoma clinical trials together with multiple large "real world" institutional and regional cancer registries across North America, Europe, and Australia. Applying rigorous data science methods, we created a common data model with a detailed data dictionary. IPD were normalized, standardized, and harmonized, resulting in the creation of a comprehensive, annotated master database of more than 15,000 patients with newly-diagnosed Hodgkin lymphoma.
Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin Lymphoma (AHOD0831)
This collection contains data from the Children's Oncology Group (COG) Clinical Trial NCT01026220. Principle Investigator: Kara Kelly, MD (pediatric oncologist and the Chair of Roswell Park Oishei Children's Cancer and Blood Disorders Program, Buffalo, NY.). It was sponsored by NCI and performed by the Children's Oncology Group under study number AHOD0831. This phase III trial is studying how well giving combination chemotherapy together with radiation therapy works in treating young patients with newly diagnosed Hodgkin lymphoma.
Annotations for Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin Lymphoma (AHOD0831-Tumor-Annotations)
This dataset contains image annotations derived from the NCI Clinical Trial "Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin Lymphoma (AHOD0831)". The key objective of this project is to generate a large and highly curated imaging dataset of pediatric Hodgkin lymphoma patients with annotations suitable for cancer researchers and AI developers.
Classical Hodgkins Lymphoma
Whole-exome sequencing of 36 cases and whole-genome sequencing of 25 cases of classical hodgkins lymphomas and their matched normals. The cases here are only those under the age of 40 years old.
Circulating Genomic Determinants of Treatment Failure in Hodgkin Lymphoma
In this study, we show that the plasma representation of mutations exceeds the bulk tumor representation in most cases, making classic Hodgkin Lymphoma (cHL) particularly amenable to noninvasive profiling. Leveraging single-cell transcriptional profiles of cHL tumors, we demonstrate hazard ratios (HRs) circulating tumor DNA (ctDNA) shedding to be shaped by DNASE1L3, whose increased tumor microenvironment-derived expression drives high ctDNA concentrations. Using this insight, we comprehensively profile 366 patients, revealing two distinct cHL genomic subtypes with characteristic clinical and prognostic correlates, as well as distinct transcriptional and immunological profiles. Furthermore, we identify a novel class of truncating IL4R-mutations that are dependent on IL13 signaling and therapeutically targetable with IL4R blocking antibodies. Finally, we demonstrate the clinical value of pre- and on-treatment ctDNA levels for longitudinally refining cHL risk prediction, and for detection of radiographically occult minimal residual disease. Collectively, these results support the utility of noninvasive strategies for genotyping and dynamic monitoring of cHL as well as capturing molecularly distinct subtypes with diagnostic, prognostic, and therapeutic potential. All patients were treated at cancer centers across Europe and North America between 2011 and 2020. The following 3 cancer centers--Stanford, CA, USA; Bellinzona, Switzerland; and Leuven, Belgium--were included.
Dataset related to article "Peripheral Blood Stem Cells versus Bone Marrow for T Cell-Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide in Hodgkin Lymphoma."
<p>Haploidentical stem cell transplantation (haplo-SCT) with post-transplant cyclophosphamide (PT-Cy) represents a potential curative strategy for patients with Hodgkin lymphoma (HL) when a matched related or unrelated donor is not available. The role of graft source, either bone marrow (BM) or peripheral blood stem cells (PBSCs), in this setting has not been fully elucidated. We performed a retrospective study on 91 patients with HL to compare the outcome after BM (n = 53) or PBSC (n = 38) transplant. Eighty-nine patients engrafted with no difference between BM and PBSCs in terms of median time for neutrophil (20 versus 20 days, P = .405) and platelet (26 versus 26.5 days, P = .994) engraftment. With a median follow-up of 40.2 months, 100-day cumulative incidences of grades II to IV acute graft-versus host disease (GVHD) and grades II to IV acute GVHD were 24% and 4%, respectively. Graft source was not associated with a different risk of acute GVHD both by univariate and multivariate analyses. Consistently, 1-year cumulative incidence of chronic GVHD was 7% with no differences between the 2 graft types (P = .761). Two-year rates of overall survival (OS), progression-free survival (PFS), nonrelapse mortality, and GVHD/relapse-free survival (GRFS) were 67%, 58%, 20%, and 52%, respectively. By univariate analysis, pretransplant disease status was the main variable affecting all outcomes. By multivariate analysis, PBSCs resulted in a protective factor for OS (hazard ratio [HR], .29; P = .006), PFS (HR, .38; P = .001), and GRFS (HR, .44; P = .020). The other independent variables affecting the final outcome were pretransplant disease status and hematopoietic cell transplant-specific comorbidity index. In conclusion, when planning a haplo-SCT with PT-Cy for patients with poor-risk HL, graft type is an important variable to take into account when selecting the best available donor.</p>
Dataset related to article: "Intensity modulated proton therapy compared to volumetric modulated arc therapy in the irradiation of young female patients with hodgkin's lymphoma. Assessment of risk of toxicity and secondary cancer induction"
<p>This record contains data related to article: "Intensity modulated proton therapy compared to volumetric modulated arc therapy in the irradiation of young female patients with hodgkin's lymphoma. Assessment of risk of toxicity and secondary cancer induction"</p> <p>Abstract</p> <p><strong>Background: </strong> To investigate the role of intensity modulated proton therapy (IMPT) compared to volumetric modulated arc therapy (VMAT) for advanced supradiaphragmatic Hodgkin's lymphoma (HL) in young female patients by assessing dosimetric features and modelling the risk of treatment related complications and radiation-induced secondary malignancies.</p> <p><strong>Methods: </strong> A group of 20 cases (planned according to the involved-site approach) were retrospectively investigated in a comparative planning study. Intensity modulated proton plans (IMPT) were compared to VMAT RapidArc plans (RA). Estimates of toxicity were derived from normal tissue complication probability (NTCP) calculations with either the Lyman or the Poisson models for a number of endpoints. Estimates of the risk of secondary cancer induction were determined for lungs, breasts, esophagus and thyroid. A simple model-based selection strategy was considered as a feasibility proof for the individualized selection of patients suitable for proton therapy.</p> <p><strong>Results: </strong> IMPT and VMAT plans resulted equivalent in terms of target dose distributions, both were capable to ensure high coverage and homogeneity. In terms of conformality, IMPT resulted ~ 10% better than RA plans. Concerning organs at risk, IMPT data presented a systematic improvement (highly significant) over RA for all organs, particularly in the dose range up to 20Gy. This lead to a composite average reduction of NTCP of 2.90 ± 2.24 and a reduction of 0.26 ± 0.22 in the relative risk of cardiac failures. The excess absolute risk per 10,000 patients-years of secondary cancer induction was reduced, with IMPT, of 9.1 ± 3.2, 7.2 ± 3.7 for breast and lung compared to RA. The gain in EAR for thyroid and esophagus was lower than 1. Depending on the arbitrary thresholds applied, the selection rate for proton treatment would have ranged from 5 to 75%.</p> <p><strong>Conclusion: </strong> In relation to young female patients with advanced supradiaphragmatic HL, IMPT can in general offer improved dose-volume sparing of organs at risk leading to an anticipated lower risk of early or late treatment related toxicities. This would reflect also in significantly lower risk of secondary malignancies induction compared to advanced photon based techniques. Depending on the selection thresholds and with all the limits of a non-validated and very basic model, it can be anticipated that a significant fraction of patients might be suitable for proton treatments if all the risk factors would be accounted for.</p> <p> </p>
Dataset related to article "18F-FDG PET/CT for response assessment in Hodgkin lymphoma undergoing immunotherapy with checkpoint inhibitors "
<p>This record contains raw data related to article 18F-FDG PET/CT for response assessment in Hodgkin lymphoma undergoing immunotherapy with checkpoint inhibitors</p> <p>Our aim was to evaluate Hodgkin Lymphoma (HL) response to checkpoint inhibitors with <sup>18</sup>F-FDG PET/CT. Forty three refractory or relapsed HL patients were investigated before immunotherapy, 8 weeks and 17 weeks after administration of either nivolumab or pembrolizumab. The median follow-up was 19 months. Best clinical response was complete response (CR) in 26 patients, partial response (PR) in 5 patients, stable disease (SD) in 8 patients, and progression disease (PD) in 4 patients. At the early assessment, Deauville Score (DS) resulted significantly different in responder group compared to nonresponders. SUVmax was significantly lower in responders, while there was no relevant modification in the tumor burden. At interim evaluation, DS well differentiated responder group. A significant decrease in glucose metabolism and tumor burden parameters was observed in responder patients, who presented with a longer progression-free survival then nonresponders. <sup>18</sup>F-FDG PET/CT provides a reliable indication of treatment response under checkpoints inhibitors, even at an early assessment.</p>
Monoclonal Antibody Treatment for Non-Hodgkin's Lymphoma (Low-Grade)
ClinicalTrials.gov study NCT00044902. IPD Sharing: Not stated. Countries: 0. Publications: 0.
This is a Multi-center, Single Arm, Open Label Study Intended to Provide Expanded Access to Plerixafor for Patients With Non-Hodgkin's Lymphoma (NHL), Hodgkin's Disease (HD) or Multiple Myeloma (MM) W
ClinicalTrials.gov study NCT00720603. IPD Sharing: Not stated. Countries: 0. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.